Recent Publications
  • Murray M., McIntosh M., Atkinson C., Mahungu T., Wright E., Chatterton W., Gandy M. & Reeves M (2021) Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay. J. Infect. Manuscript Accepted.

 

  • Siddiqui S., Hackl S., Ghoddusi H., McIntosh M, Ho J., Gomes A., Reeves M. & McLean G. (2020) IgA binds to the AD-2 epitope of glycoprotein B and neutralises human cytomegalovirus infection. Immunology  doi: 10.1111/imm.13286

 

  • Houldcroft C., Jackson S., Lim E., Sedikes G., Davies E., Atkinson C., McIntosh M., Remmerswaal E., Okecha G., Bemelman F., Stanton R., Reeves M. & Wills M. (2020) Assessing anti-HCMV cell mediated immune responses in transplant recipients and healthy controls using a novel functional assay. Front. Cell. Infect. Micro. 10:275

 

  • Mason R., Groves I.J., Wills M.R., Sinclair J.H. & Reeves M.B. (2020) Human cytomegalovirus major immediate-early transcripts arise predominantly from the canonical major immediate early promoter in reactivating progenitor-derived dendritic cells. J. Gen. Virol. 101(6):635-44

  • M.J. Murray, N.I. Bonilla-Medrano, Q.L. Lee, S.J. Oxenford, R. Angell, D.P. Depledge, M.B. Reeves (2020) Evasion of a human cytomegalovirus entry inhibitor with potent cysteine reactivity is concomitant with the utilisation of a heparan sulfate proteoglycan independent route of entry.  Journal of Virology, JVI.02012-19; DOI: 10.1128/JVI.02012-19

  • Baraniak, I., Gomes, A., Sodi, I., Langstone, T., Rothwell, E., Atkinson, C., Piras-Douce, F., Pichon, S., Griffiths, P. & Reeves M.B. (2019) Seronegative patients vaccinated with the cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation Lancet EBioMedicine 50:45-54

  • Dupont L, Du L, Poulter M, Choi S, McIntosh M, Reeves MB. (2019). Src family kinase activity drives cytomegalovirus reactivation by recruiting MOZ histone acetyltransferase activity to the viral promoter. J Biol Chem 294:jbc.RA119.009667.
     

  •  Baraniak I., Kern F., Holenya P., Griffiths P.D. & Reeves M.B. (2019) Original antigenic sin shapes the immunological repertoire evoked by HCMV gB-MF59 vaccine in seropositive recipients. J. Inf. Dis. pii:jiz089

  • Alsaady I, Tedford E, Alsaad M, Bristow G, Kohli S, Murray M, Reeves M, Vijayabaskar MS, Clapcote SJ, Wastling J, McConkey GA. (2019). Downregulation of the central noradrenergic system by Toxoplasma gondii infection. Infect Immun 87:e0078918. https://doi.org/10.1128/IAI.00789-18.
     

  • Poole E.L., Lau J.C.H., Murray, M.J., Kew V.G., Stamminger T., Sinclair J.H. & Reeves M.B. (2018) A virally dependent de-sumoylase activity is required for HCMV reactivation from latency Cell Reports 24(3):594-606. Highlighted in Faculty 1000.

  • Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean, G, Pichon S,Atkinson C, Milne R.,Mach, M., Griffiths P. & Reeves M.B. (2018) Protection from cytomegalovirus viraemia following glycoprotein B vaccination is not dependent on neutralising antibodies PNAS 115(24):6273-6278

  • Also see editorial: Schleiss M.R. Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection

 

  • Baraniak I.... Reeves M.B. (2018) Epitope mapping of the humoral immune response against HCMV glycoprotein B following vaccination with gB/MF59 prior to transplant. Journal of Infectious Diseases jiy102, https://doi.org/10.1093/infdis/jiy102

 

 

​REVIEWS/ EDITORIALS/ PERSPECTIVES

 

  • Forrest C., Gomes A., Reeves M. & Male V. (2020) NK cell memory to cytomegalovirus: Implications for vaccine development. Vaccines 8(3):E394

 

  • Reeves M.B. (2020) Cell signalling and cytomegalovirus reactivation: what do src family kinases have to do with it? Biochem. Soc. Trans. 48(2): 667-75

 

  • Nelson C.S., Baraniak I., Lilleri D., Reeves M.B., Griffiths P.D. & Permar S.R. (2020) Immune correlates of protection against human cytomegalovirus acquisition, replication and disease. J. Inf. Dis. 221: S45-59

  • Gomes, A.C.; Griffiths, P.D.; Reeves, M.B. The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. Vaccines 2019, 7, 67.
     

  • Chong, S, Antoni, M, Macdonald, A, Reeves, M, Harber, M, Magee, CN. BK virus: Current understanding of pathogenicity and clinical disease in transplantation. Rev Med Virol. 2019; 29:e2044. https://doi.org/10.1002/rmv.2044
     

  • Murray M.J., Peters, N.E. & Reeves M.B. (2018) Navigating the host cell response during entry into sites of latent cytomegalovirus infection. Pathogens 7(1). pii: E30.

 

  • Reeves M.B. (2018) Viral programming of progenitor cell commitment Nat. Micro.4: 398-99

 

  • Baraniak I., Reeves M.B. & Griffiths P. (2018) Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient Rev. Med. Virol. 28(1): doi: 10.1002/rmv.1958

Key Publications
  • Mason R., Groves I.J., Wills M.R., Sinclair J.H. & Reeves M.B. (2020) Human cytomegalovirus major immediate-early transcripts arise predominantly from the canonical major immediate early promoter in reactivating progenitor-derived dendritic cells. J. Gen. Virol. 101(6):635-44

  • Baraniak, I., Gomes A., Sodi I., Langstone T., Rothwell E., Atkinson C., Piras-Douce F., Pichon S., Griffiths P. & Reeves M.B. (2019) Seronegative patients vaccinated with the cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation Lancet EBioMedicine 50:45-54

 

  • Dupont L., Du L., Poulter M., Choi S., McIntosh M. & Reeves M.B. (2019) Src family kinase activity drives cytomegalovirus reactivation through recruitment of MOZ histone acetyltransferase activity J. Biol. Chem. 294(35):12901-1291

  • Poole E.L., Lau J.C.H., Murray, M.J., Kew V.G., Stamminger T., Sinclair J.H. & Reeves M.B. (2018) A virally dependent de-sumoylase activity is required for HCMV reactivation from latency Cell Reports 24(3):594-606

  • Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean, G, Pichon S,Atkinson C, Milne R.,Mach, M., Griffiths P. & Reeves M.B. (2018) Protection from cytomegalovirus viraemia following glycoprotein B vaccination is not dependent on neutralising antibodies PNAS 115(24):6273-627

  • Baraniak I.... Reeves M.B. (2018) Epitope mapping of the humoral immune response against HCMV glycoprotein B following vaccination with gB/MF59 prior to transplant. Journal of Infectious Diseases jiy102, https://doi.org/10.1093/infdis/jiy102

  • Kew V.G., Yuan, J., Meier, J. & Reeves M.B. (2014) Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus gene expression from latency. PLoS Pathogens10(6):e1004195

 

  • Huang M.M., Kew V.G., Jestice K., Wills M.R. & Reeves M.B. (2012) Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. J. Virol. 86(16):8507-15

 

  • Reeves M.B., Breidenstein A. & Compton T. (2012) Human cytomegalovirus activation of ERK and myeloid cell leukaemia-1 protein correlates with survival of latently infected cells. PNAS 109(2): 588-93

 

  • Reeves M.B. & Compton T. (2011) Inhibition of inflammatory interleukin-6 activity via extracellular signal-related-mitogen activated protein kinase antagonizes human cytomegalovirus reactivation from dendritic cells. J. Virol. 85(23): 12750-8

 

  • Reeves M.B., Davies A.A., McSharry B.P., Wilkinson G.W. and Sinclair J.H. (2007) A virally encoded RNA molecule protects infected cells from mitochondrial-induced cell death. Science 316(5829): 1345-8 see also Perspectives section in Science 317(5836):  329-30

  • Reeves M.B., Lehner P.J., Sissons J.G.P. and Sinclair J.H. (2005) An in vitro model for the regulation of HCMV latency and reactivation in dendritic cells by chromatin remodeling. J. Gen. Virol 86(11): 2949-54

 

  • Reeves M.B., MacAry P.A., Lehner P.J., Sissons J.G.P. and Sinclair J.H. (2005) Latency, chromatin remodeling and reactivation of HCMV in the dendritic cells of healthy carriers. PNAS 102(11): 4140-5